IL161573A0 - [1,2,4]-TRIAZOLE BICYCLIC ADENOSINE A2a RECEPTOR ANTAGONISTS - Google Patents

[1,2,4]-TRIAZOLE BICYCLIC ADENOSINE A2a RECEPTOR ANTAGONISTS

Info

Publication number
IL161573A0
IL161573A0 IL16157302A IL16157302A IL161573A0 IL 161573 A0 IL161573 A0 IL 161573A0 IL 16157302 A IL16157302 A IL 16157302A IL 16157302 A IL16157302 A IL 16157302A IL 161573 A0 IL161573 A0 IL 161573A0
Authority
IL
Israel
Prior art keywords
adenosine
receptor antagonists
triazole
bicyclic
triazole bicyclic
Prior art date
Application number
IL16157302A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of IL161573A0 publication Critical patent/IL161573A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL16157302A 2001-11-30 2002-11-26 [1,2,4]-TRIAZOLE BICYCLIC ADENOSINE A2a RECEPTOR ANTAGONISTS IL161573A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33438501P 2001-11-30 2001-11-30
PCT/US2002/037915 WO2003048163A1 (en) 2001-11-30 2002-11-26 [1,2,4]-TRIAZOLE BICYCLIC ADENOSINE A2a RECEPTOR ANTAGONISTS

Publications (1)

Publication Number Publication Date
IL161573A0 true IL161573A0 (en) 2004-09-27

Family

ID=23306955

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16157302A IL161573A0 (en) 2001-11-30 2002-11-26 [1,2,4]-TRIAZOLE BICYCLIC ADENOSINE A2a RECEPTOR ANTAGONISTS

Country Status (19)

Country Link
US (2) US6875772B2 (xx)
EP (1) EP1453836B1 (xx)
JP (2) JP4429724B2 (xx)
KR (1) KR20050044600A (xx)
CN (1) CN1688581A (xx)
AR (1) AR037681A1 (xx)
AT (1) ATE358130T1 (xx)
AU (1) AU2002352933A1 (xx)
CA (1) CA2468658C (xx)
DE (1) DE60219196T2 (xx)
ES (1) ES2283625T3 (xx)
HK (1) HK1064097A1 (xx)
HU (1) HUP0402324A3 (xx)
IL (1) IL161573A0 (xx)
MX (1) MXPA04005158A (xx)
PE (1) PE20030653A1 (xx)
TW (1) TW200300689A (xx)
WO (1) WO2003048163A1 (xx)
ZA (1) ZA200404168B (xx)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20030739A1 (es) 2001-11-30 2003-08-28 Schering Corp Antagonistas del receptor de adenosina a2a
ATE358130T1 (de) * 2001-11-30 2007-04-15 Schering Corp Bicyclische (1,2,4ö-triazol adenosin a2a rezeptor antagonisten
JP2005527530A (ja) * 2002-03-12 2005-09-15 ワイス キラル１，４−二置換ピペラジン
CA2500228A1 (en) * 2002-09-24 2004-04-08 Kyowa Hakko Kogyo Co., Ltd. [1,2,4]-triazolo[1,5-c]pyrimidine derivative
ES2354875T3 (es) 2002-12-19 2011-03-18 Schering Corporation Uso de antagonistas del receptor a2a de la adenosina para el tratamiento o prevención del síndrome extrapiramidal.
EP1618109A2 (en) * 2003-04-09 2006-01-25 Biogen Idec MA Inc. Triazolo[1,5-c]pyrimidines and pyrazolo[1,5-c]pyrimidines useful as a2a adenosine receptor antagonists
WO2004092170A2 (en) 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolotriazines and pyrazolotriazines useful as a2a adenosine receptor antagon ists
US7674791B2 (en) 2003-04-09 2010-03-09 Biogen Idec Ma Inc. Triazolopyrazines and methods of making and using the same
EP1633756B1 (en) 2003-04-09 2008-12-24 Biogen Idec MA Inc. A2a adenosine receptor antagonists
TW200507850A (en) * 2003-07-25 2005-03-01 Kyowa Hakko Kogyo Kk Pharmaceutical composition
WO2006129626A1 (ja) * 2005-05-30 2006-12-07 Kyowa Hakko Kogyo Co., Ltd. [1,2,4]トリアゾロ[1,5-c]ピリミジン誘導体の製造法
US7851478B2 (en) 2005-06-07 2010-12-14 Kyowa Hakko Kirin Co., Ltd. Agent for preventing and/or treating movement disorder
WO2006131524A1 (en) * 2005-06-08 2006-12-14 Neurosearch A/S Novel n-phenyl-piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
TW200803856A (en) * 2005-09-02 2008-01-16 Mount Cook Biosciences Inc Method of treating parkinson's disease with diarylmethylpiperazine compounds exhibiting delta receptor agonist activity
ES2273599B1 (es) 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
US7615556B2 (en) * 2006-01-27 2009-11-10 Bristol-Myers Squibb Company Piperazinyl derivatives as modulators of chemokine receptor activity
US20110064671A1 (en) 2008-03-10 2011-03-17 Cornell University Modulation of blood brain barrier permeability
WO2010008775A1 (en) * 2008-06-23 2010-01-21 Ligand Pharmaceuticals Inc. Aminopyridopyrazinone derivatives for treating neurodegenerative diseases
GB201214106D0 (en) * 2012-08-07 2012-09-19 Univ Strathclyde Immunomodulatory compounds
EP3436013A4 (en) 2016-03-31 2019-11-13 Versi Group, LLC COMPOSITIONS BASED ON OPIACE RECEPTOR DELTA / OPAACEOUS RECEPTOR DELTA OPTIONAL AGONIST, AND METHODS FOR TREATING PARKINSON'S DISEASE
CN106866582A (zh) * 2017-01-10 2017-06-20 广州隽沐生物科技有限公司 一种氟班色林中间体的制备方法
CA3103068C (en) 2018-06-26 2024-06-25 Zhejiang Vimgreen Pharmaceuticals, Ltd Triazolotriazine derivatives as a2a receptor antagonists
WO2020227156A1 (en) * 2019-05-03 2020-11-12 Nektar Therapeutics Adenosine 2 receptor antagonists
WO2022224180A1 (en) * 2021-04-23 2022-10-27 Chong Kun Dang Pharmaceutical Corp. Compound as adenosine a2a receptor antagonist and pharmaceutical composition comprising same

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1264901B1 (it) 1993-06-29 1996-10-17 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina
CA2144330A1 (en) * 1993-07-27 1995-02-09 Fumio Suzuki A therapeutic agent for parkinson's disease
IT1277392B1 (it) 1995-07-28 1997-11-10 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina
CA2284737C (en) * 1997-03-24 2007-03-13 Kyowa Hakko Kogyo Co., Ltd. [1,2,4]triazolo[1,5-c]pyrimidine derivatives
IT1291372B1 (it) 1997-05-21 1999-01-07 Schering Plough S P A Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
AU2639299A (en) * 1998-02-24 1999-09-15 Kyowa Hakko Kogyo Co. Ltd. Remedies/preventives for parkinson's disease
EA200100265A1 (ru) * 1998-09-22 2001-10-22 Киова Хакко Когио Ко., Лтд. Производные [1,2,4]триазоло[1,5-c]пиримидина
US6355653B1 (en) 1999-09-06 2002-03-12 Hoffmann-La Roche Inc. Amino-triazolopyridine derivatives
JP2002037787A (ja) * 2000-05-16 2002-02-06 Kyowa Hakko Kogyo Co Ltd ［１，２，４］トリアゾロ［１，５−ｃ］ピリミジン誘導体の製造法
ES2237576T3 (es) 2000-05-26 2005-08-01 Schering Corporation Antagonistas del receptor a2a de adenosina.
PE20030477A1 (es) * 2001-10-15 2003-06-06 Schering Corp ANTAGONISTAS DEL RECEPTOR DE ADENOSINA A2a
ATE358130T1 (de) * 2001-11-30 2007-04-15 Schering Corp Bicyclische (1,2,4ö-triazol adenosin a2a rezeptor antagonisten

Also Published As

Publication number Publication date
AR037681A1 (es) 2004-12-01
CA2468658C (en) 2009-04-14
JP4429724B2 (ja) 2010-03-10
DE60219196T2 (de) 2008-01-03
ES2283625T3 (es) 2007-11-01
MXPA04005158A (es) 2004-08-11
JP2005511697A (ja) 2005-04-28
HUP0402324A2 (hu) 2005-02-28
KR20050044600A (ko) 2005-05-12
US7078408B2 (en) 2006-07-18
DE60219196D1 (de) 2007-05-10
HK1064097A1 (en) 2005-01-21
US20050113380A1 (en) 2005-05-26
US6875772B2 (en) 2005-04-05
TW200300689A (en) 2003-06-16
HUP0402324A3 (en) 2008-09-29
ZA200404168B (en) 2005-09-02
WO2003048163A1 (en) 2003-06-12
JP2010018634A (ja) 2010-01-28
US20030191130A1 (en) 2003-10-09
EP1453836A1 (en) 2004-09-08
EP1453836B1 (en) 2007-03-28
PE20030653A1 (es) 2003-08-04
ATE358130T1 (de) 2007-04-15
CA2468658A1 (en) 2003-06-12
AU2002352933A1 (en) 2003-06-17
CN1688581A (zh) 2005-10-26

Similar Documents

Publication Publication Date Title
IL161573A0 (en) [1,2,4]-TRIAZOLE BICYCLIC ADENOSINE A2a RECEPTOR ANTAGONISTS
IL161572A0 (en) Adenosine a2a receptor antagonists
IL152726A0 (en) Adenosine a2a receptor antagonists
IL161716A0 (en) ADENOSINE A2a RECEPTOR ANTAGONISTS
HUP0401925A3 (en) A2b adenosine receptor antagonists
IL160878A0 (en) Imidazo (4,3-e)-1,2,4-triazolo (1,5-c) pyrimidines as adenosine a2a receptor antagonists
HUP0401437A3 (en) Adenosine a3 receptor agonists
MXPA03004439A (es) Aminotiazoles y su uso como antagonistas del receptor de adenosina.
IL147198A0 (en) N-pyrazole a2a receptor agonists
IL147195A0 (en) C-pyrazole a2a receptor agonists
TWI365879B (en) A2b adenosine receptor antagonists
PL373953A1 (en) 7-amino-benzothiazole derivatives as adenosine receptor ligands
SG80041A1 (en) Muscarinic receptor antagonists
ZA200408755B (en) Condensed purine derivatives as A1 adenosine receptor antagonists.
HK1049835A1 (en) Selective antagonists of a2b adenosine receptors a2b.
PL353366A1 (en) Pyrazolo[4,3-d]pyrimidines
HK1038919A1 (zh) 作為速激肽受體拮抗劑的萘甲酰胺
IL162444A0 (en) Triazolo-quinolin derivatives useful as adenosine receptor ligands
PL370565A1 (en) 5-methoxy-8-aryl-[1,2,4] triazolo [1,5-a] pyridine derivatives as adenosine receptor antagonists
AU4980999A (en) A3 adenosine receptor antagonists
GB0101223D0 (en) Histamine receptor antagonists
IL158063A0 (en) Crf receptor antagonists
SI1444233T1 (sl) Antagonisti adenozinskega receptorja A2B
AU2002226519A1 (en) Pyrrolo(2,3-d)pyrimidine and their use as purinergic receptor antagonists
HUP0203369A3 (en) Polycycloalkylpurines as adenosine receptor antagonists, process for their preparation and their use